Dimension Therapeutics sold for $138 million

Ultragenyx to acquire Dimension Therapeutics for $5.50 per share in cash

Ultragenyx to acquire Dimension Therapeutics for $5.50 per share in cash. See Stockwinners.com for details

Ultragenyx Pharmaceutical (RARE) announced that it has made a proposal to acquire all of the outstanding shares of common stock of Dimension Therapeutics (DMTX) for $5.50 per share, or approximately $138 million, in cash at close to be effectuated via a tender offer.

The Ultragenyx offer represents a premium of over 358% to Dimension’s unaffected share price as of August 24, 2017 and premiums of 24% and 48% over the implied value of the all-stock consideration to be received by Dimension stockholders pursuant to the announced acquisition of Dimension by REGENXBIO (RGNX), based on REGENXBIO’s last closing price and trailing 20-trading day volume-weighted average price as of September 15, 2017, respectively.

As such, the proposal would provide Dimension stockholders with an immediate and certain return on their investment in Dimension and constitutes a superior alternative to the REGENXBIO transaction.

The proposal has been approved by the Board of Directors of Ultragenyx. Ultragenyx would fund the transaction from cash resources on its balance sheet and anticipates that customary closing conditions to the transaction could be satisfied so that the tender offer could complete as soon as 25 business days after merger agreement signing.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Leave a Reply

Your email address will not be published. Required fields are marked *